October 24, 2018 05:24 AM EDT
R&D

Amid re­peat­ed stum­bles, Pfiz­er and Eli Lil­ly tout their an­ti-NGF pain drug tanezum­ab — but ques­tions linger

John Carroll

Editor & Founder

Pfiz­er and Eli Lil­ly have start­ed to make their late-stage case for tanezum­ab, out­lin­ing some pos­i­tive re­sults on pain but rais­ing some se­ri­ous is­sues about …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times